Investigation of a new tumor-associated glycosylated antigen as target for dendritic cell vaccination in pancreatic cancer.
Glycoproteins, as valuable targets for dendritic cell (DC)-vaccination in cancers, remain an open question. Glycosylated structures, which are aberrantly modified during cancerisation, impact positively or negatively on glycoprotein immunogenicity. Here is presented an oncofetal glycovariant of bile-salt-dependent-lipase, expressed on human tumoral pancreas and efficiently processed by DC's, inducing T-lymphocyte activation.
INSERM; Marseille, France; Aix-Marseille Univ ; Centre de Recherche en Oncologie biologique et Oncopharmacologie; Marseille, France.
Evelyne
E
Béraud
Aurélie
A
Collignon
Cécile
C
Franceschi
Daniel
D
Olive
Dominique
D
Lombardo
Eric
E
Mas